Baidu
map

Cancer:NF-kB多态性与肺癌发病风险降低相关

2012-12-10 T.Shen 生物谷

    近日,刊登在国际著名癌症杂志Cancer上的一项研究报告指出,一种涉及炎症和免疫效应的基因突变和肺癌发病风险降低直接相关。     这项研究由国立癌症研究中心的研究者进行,研究中,研究者对378位肺癌病人和450位健康个体中涉及炎症和免疫效应的1429个突变进行了分析,结果显示,肺癌和位于44个基因处的81个单核苷酸多态性(SN

    近日,刊登在国际著名癌症杂志Cancer上的一项研究报告指出,一种涉及炎症和免疫效应的基因突变和肺癌发病风险降低直接相关。

    这项研究由国立癌症研究中心的研究者进行,研究中,研究者对378位肺癌病人和450位健康个体中涉及炎症和免疫效应的1429个突变进行了分析,结果显示,肺癌和位于44个基因处的81个单核苷酸多态性(SNPs)直接相关。

    随后,研究者对比分析了结果,同时分析了对5739位肺癌患者以及5848个健康个体的全基因组向关联分析的结果,发现在81个SNPs中,名为rs4648127,位于基因NFKB1处的SNP和肺癌都具有明显的相关性,而且该SNP和肺癌风险降低相关,可以使得肺癌风险降低约44%。

    NF-kB或者细胞核因子kB,是NFKB1基因产生的一种重要的蛋白质,其通过调节基因表达、细胞死亡、增殖,在机体免疫系统和炎症反应上扮演着重要角色。此前研究表明,免疫反应和炎症或许会影响肺癌的发生,在这项研究中,研究者的研究结果揭示了炎症和肺癌发生之间存在相关性。后期研究者们还将继续研究NFKB1以及其和肺癌发生的关系。

肺癌相关的拓展阅读:

编译自:Gene Variant Linked With Reduced Lung Cancer Risk

doi:10.1002/cncr.27605
PMC:
PMID:

Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk

Meredith S. Shiels PhD, MHS1,¶,*, Eric A. Engels MD, MPH1, Jianxin Shi PhD2, Maria Teresa Landi MD, PhD3, Demetrius Albanes MD4, Nilanjan Chatterjee PhD2, Stephen J. Chanock MD5, Neil E. Caporaso MD3, Anil K. Chaturvedi PhD1

BACKGROUND: Pulmonary inflammation may contribute to lung cancer etiology. The authors conducted a broad evaluation of the association of single nucleotide polymorphisms (SNPs) in innate immunity and inflammation pathways with lung cancer risk and conducted comparisons with a lung cancer genome-wide association study (GWAS).

METHODS: In total, 378 patients with lung cancer (cases) and a group of 450 controls from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial were included. A proprietary oligonucleotide pool assay was used to genotype 1429 SNPs. Odds ratios and 95% confidence intervals were estimated for each SNP, and P values for trend (Ptrend) were calculated. For statistically significant SNPs (Ptrend < .05), the results were replicated with genotyped or imputed SNPs in the GWAS, and P values were adjusted for multiple testing.

RESULTS: In the PLCO analysis, a significant association was observed between lung cancer and 81 SNPs located in 44 genes (Ptrend < .05). Of these 81 SNPS, there was evidence for confirmation in the GWAS for 10 SNPs. However, after adjusting for multiple comparisons, the only SNP that retained a significant association with lung cancer in the replication phase was reference SNP rs4648127 (nuclear factor of kappa light polypeptide gene enhancer of B-cells 1 [NFKB1]) (multiple testing-adjusted Ptrend = .02). The cytosine-thymine (CT)/TT genotype of NFKB1 was associated with reduced odds of lung cancer in the PLCO study (odds ratio, 0.56; 95% confidence interval, 0.37-0.86) and the in the GWAS (odds ratio, 0.79; 95% confidence interval, 0.69-0.90).

CONCLUSIONS: A significant association was observed between a variant in the NFKB1 gene and the risk of lung cancer. The current findings add to evidence implicating inflammation and immunity in lung cancer etiology. Cancer 2012. Published 2012 by the American Cancer Society.

(责任编辑:yan.mao)

分享到:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799763, encodeId=cd091e9976324, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sun Sep 15 08:16:00 CST 2013, time=2013-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820621, encodeId=0c031820621d2, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sun May 12 06:16:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536954, encodeId=c49f153695446, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Dec 12 04:16:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629181, encodeId=f0dd16291810a, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Dec 12 04:16:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799763, encodeId=cd091e9976324, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sun Sep 15 08:16:00 CST 2013, time=2013-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820621, encodeId=0c031820621d2, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sun May 12 06:16:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536954, encodeId=c49f153695446, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Dec 12 04:16:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629181, encodeId=f0dd16291810a, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Dec 12 04:16:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799763, encodeId=cd091e9976324, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sun Sep 15 08:16:00 CST 2013, time=2013-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820621, encodeId=0c031820621d2, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sun May 12 06:16:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536954, encodeId=c49f153695446, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Dec 12 04:16:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629181, encodeId=f0dd16291810a, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Dec 12 04:16:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
    2012-12-12 仁医06
  4. [GetPortalCommentsPageByObjectIdResponse(id=1799763, encodeId=cd091e9976324, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Sun Sep 15 08:16:00 CST 2013, time=2013-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820621, encodeId=0c031820621d2, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Sun May 12 06:16:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536954, encodeId=c49f153695446, content=<a href='/topic/show?id=f1c512e304f' target=_blank style='color:#2F92EE;'>#NF-kB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12730, encryptionId=f1c512e304f, topicName=NF-kB)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Dec 12 04:16:00 CST 2012, time=2012-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629181, encodeId=f0dd16291810a, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Dec 12 04:16:00 CST 2012, time=2012-12-12, status=1, ipAttribution=)]
    2012-12-12 xzw120

相关资讯

PLoS ONE:细胞刚度能够预测卵巢癌细胞的转移潜力

    在一项新研究中,来自佐治亚理工学院的研究人员证实当医生在癌细胞能够扩散之前找到和治疗它们时,细胞刚度(cell stiffness)可能很有价值。他们发现高度转移性卵巢癌细胞要比转移能力较差的卵巢癌细胞柔软好几倍。相关研究结果于近日刊登在PLoS ONE期刊上。     助理教授Todd Sulchek和博士研究生Wenwei

Nat Genet:外显子测序显示数种体细胞突变可导致子宫内膜癌

  近期发表的《自然—遗传学》报道了数种可影响子宫内膜,导致子宫内膜癌发生的复发性体细胞突变。   子宫内膜癌是世界第六大女性常见癌症。Daphne Bell等人对13种主要的浆液性子宫内膜肿瘤进行了外显子测序。他们对18种基因进行患病筛查,发现另有40种浆液性子宫内膜肿瘤存在复发性。通过主要 组织学亚型的比较,Bell和同事在23个透明细胞、67个子宫内膜样本和18个混合型子宫内膜肿瘤对

NEJM:培养出肺部“微型肿瘤”用于体外筛查药物

    这是一个医疗噩梦:一名24岁的男子自童年开始经历了350次手术以清除在他的喉咙中持续复发,且已扩散至肺部威胁他生命的生长物。现在医生们找到了一种途径通过一种科学变革方法可以帮助到他,从而为成百上千万的癌症患者带来了希望。     这一离奇病例是第一次将一个如何在实验室中维持正常细胞和癌细胞存活的新发现运用到患者身上。 &nbs

Nat Commun:粘附分子帮助癌细胞挣脱原位转移至新组织

   肿瘤转移是导致90%癌症患者死亡的主要原因之一,但癌细胞从身体的一个部位扩散到另一组织器官的确切机制仍被完全阐明,一个关键问题是肿瘤细胞是如何从原位肿瘤组织脱离,然后定位于新的器官继续生长的。     近日,麻省理工学院(MIT)癌症研究人员的一项新研究揭示了一些细胞粘附分子在肿瘤细胞这一过程中发挥关键作用。相关研究结果发表在10月9日的N

PLoS ONE:新型3D模型助力癌症研究

    近日,刊登在国际杂志PLoS One上的一项研究揭示了一种新型技术,其可以通过在三维角度植入肺癌细胞来帮助科学家快速发现特定的癌症病灶。这种新型的3D模型由美以美医院等处的研究者开发。研究者表示,我们设计的3D模型在肺癌研究中很多方面优于2D模型。     新型的肺癌研究模型对于研究者来说非常重要,因为当前的模型并不能加速人类的

JNCI:饮食血糖负荷增加III期结肠癌患者肿瘤复发风险

    在结肠癌患者中,血糖负荷对其生存情况影响目前还知之甚少。为了解决上述问题,Jeffrey A. Meyerhardt等进行了相关研究,其研究结果发表在JNCI 11月最新的在线期刊上。    这个研究是前瞻性、观察性研究,研究纳入了1011名III期结肠癌患者,要求这些患者记录其在接受辅助化疗期间和之后6个月的饮食摄入情况。研究者

Baidu
map
Baidu
map
Baidu
map